Invention Grant
- Patent Title: Controlled-release PTH compound
-
Application No.: US18063294Application Date: 2022-12-08
-
Publication No.: US11890326B2Publication Date: 2024-02-06
- Inventor: Kennett Sprogøe , Felix Cleemann , Guillaume Maitro , Mathias Krusch , Thomas Wegge , Joachim Zettler
- Applicant: ASCENDIS PHARMA BONE DISEASES A/S
- Applicant Address: DK Hellerup
- Assignee: ASCENDIS PHARMA BONE DISEASES A/S
- Current Assignee: ASCENDIS PHARMA BONE DISEASES A/S
- Current Assignee Address: DK Hellerup
- Agency: Alston & Bird LLP
- Priority: EP 191451 2016.09.29 EP 155843 2017.02.13
- Main IPC: A61K38/29
- IPC: A61K38/29 ; A61K47/60 ; A61K9/00 ; A61K9/16 ; A61K47/54 ; A61K47/34
Abstract:
The present invention relates to a controlled-release parathyroid hormone (PTH) compound in which PTH(1-34) is reversibly conjugated to a branched polyethylene glycol. The invention further relates to a pharmaceutical composition of the compound. The compound or pharmaceutical composition is useful for treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH.
Public/Granted literature
- US20230248836A1 Dosage Regimen for a Controlled-Release PTH Compound Public/Granted day:2023-08-10
Information query
IPC分类:
